The biological effect of $^{125}$I seed continuous low dose rate irradiation in CL187 cells
Hong-Qing Zhuang¹, Jun-Jie Wang*¹, An-Yan Liao¹, Ji-Dong Wang¹ and Yong Zhao²

Address: ¹Cancer Center, Department of Radiation Oncology, Peking University Third Hospital, Beijing 100191, PR China and ²Transplantation Biology Research Division, State Key Laboratory of Biomembrane and Membrane Biotechnology, Institute of Zoology, Chinese Academy of Sciences, Beijing 100101, PR China

Email: Hong-Qing Zhuang - hongqingzh@163.com; Jun-Jie Wang* - doctorwangjunjie@yahoo.com.cn; An-Yan Liao - liaoanyan323@126.com; Ji-Dong Wang - jidongwzs@163.com; Yong Zhao - zhaoy@ioz.ac.cn

* Corresponding author

Abstract

Background: To investigate the effectiveness and mechanism of $^{125}$I seed continuous low-dose-rate irradiation on colonic cell line CL187 in vitro.

Methods: The CL187 cell line was exposed to radiation of $^{60}$Co $\gamma$ ray at high dose rate of 2 Gy/min and $^{125}$I seed at low dose rate of 2.77 cGy/h. Radiation responses to different doses and dose rates were evaluated by colony-forming assay. Under $^{125}$I seed low dose rate irradiation, a total of 12 culture dishes were randomly divided into 4 groups: Control group, and 2, 5, and 10 Gy irradiation groups. At 48 h after irradiation, apoptosis was detected by Annexin and Propidium iodide (PI) staining. Cell cycle arrests were detected by PI staining. In order to investigate the influence of low dose rate irradiation on the MAPK signal transduction, the expression changes of epidermal growth factor receptor (EGFR) and Raf under continuous low dose rate irradiation (CLDR) and/or EGFR monoclonal antibodies were determined by indirect immunofluorescence.

Results: The relative biological effect (RBE) for $^{125}$I seeds compared with $^{60}$Co $\gamma$ ray was 1.41. Apoptosis rates of CL187 cancer cells were 13.74% ± 1.63%, 32.58% ± 3.61%, and 46.27% ± 3.82% after 2 Gy, 5 Gy, and 10 Gy irradiation, respectively; however, the control group apoptosis rate was 1.67% ± 0.19%. G₂/M cell cycle arrests of CL187 cancer cells were 42.59% ± 3.21%, 59.84% ± 4.96%, and 34.61% ± 2.79% after 2 Gy, 5 Gy, and 10 Gy irradiation, respectively; however, the control group apoptosis rate was 26.44% ± 2.53%. $P < 0.05$ vs. control groups by Student's t-test were found in every treated group both in apoptosis and in G₂/M cell cycle arrest. After low dose rate irradiation, EGFR and Raf expression increased, but when EGFR was blocked by a monoclonal antibody, EGFR and Raf expression did not change.

Conclusion: $^{125}$I seeds resulted in more effective inhibition than $^{60}$Co $\gamma$ ray high dose rate irradiation in CL187 cells. Apoptosis following G₂/M cell cycle arrest was the main mechanism of cell-killing effects under low dose rate irradiation. CLDR could influence the proliferation of cells via MAPK signal transduction.
Background
Because of its ability to offer high precision, little trauma, strong lethality, and fewer complications [1-4], 125I radioactive seed implantation has been widely applied in clinical practice for tumor treatment, such as prostate carcinoma [5], recurrent colorectal cancer [6-10], head and neck carcinoma [11,12], and others [13-15]. However, radiobiological study of continuous low dose rate irradiation (CLDR), and especially that which defines the deep development of radioactive seed implantation and its intersection with other subjects of tumor treatment, has only recently been conducted [16,17]. Therefore, further study on the basic radiobiology of continuous low dose rate irradiation is necessary, particularly to provide further clinical direction. In the present study, the CL187 colonic cell line was exposed to 125I seeds at low dose rate irradiation, and killing effect of cells cultured in vitro were observed to reveal the radiobiological mechanism of 125I radioactive seed irradiation.

Materials and methods
Reagents
Cell culture media was provided by the Zoology Institute of the Chinese Academy of Sciences. Propidium iodide (PI) and annexin V were purchased from Cell Signaling Company (Cell Signaling Technology, Beverly, MA). Phospho-P38 epidermal growth factor receptor (EGFR) mAb (Alexa Fluor) and Phospho-raf mAb (Alexa Fluor) were obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). All other materials were obtained from the Zoology Institute of the Chinese Academy of Sciences.

Cell lines and cell culture
The CL187 colonic cancer cell line was kindly provided by the Beijing Institute for Cancer Research. It was maintained in RPMI1640 supplemented with 20 mM HEPES (pH 7.4), 100 IU/mL penicillin, 100 mg/mL streptomycin, 4 mM glutamine, and 10% heat-inactivated fetal bovine serum (Hangzhou Sijiqing Biological Engineering Materials Company, China) in a humidified atmosphere of 95% air and 5% CO2 at 37°C.

125I seeds irradiation
We used our in-house developed in vitro iodine-125 seed irradiation model shown in Figure 1[18]. The model consists of a 3-mm thick polystyrene panel, with a lower seed plaque layer and an upper cell culture plaque layer. In the seed plaque, 14 seeds with the same activity were equally spaced within recesses (4.5 mm × 0.8 mm) around a 35-mm diameter (D) circumference. In the cell culture plaque, the same recesses were made around a 35-mm D circumference; its center was along the same vertical line as that of the seed plaque, so that a 35-mm Petri dish could be placed on it during the experiment. The height (H) between the seed plaque and the bottom of Petri dish was 12 mm, with a D/H ratio of 2.9. The purpose of this design was to obtain a relatively homogeneous dose distribution at the bottom of the Petri dish. The polystyrene assembly was enclosed by a 3-mm thick lead chamber.
with a vent-hole, so that during the study the whole model could be kept in the incubator. The incubator played a protective role by maintaining constant cell culture conditions. Model 6711 $^{125}$I seeds were provided by Ningbo Junan Pharmaceutical Technology Company, China. The single seed activity used in this study was 92.5 MBq (2.5 mCi), corresponding initial dose rate in model cells was 2.77 cGy/h. The dose uniformity of the irradiation model in the cell plane was 1.34, which was similar to other investigators’ results [2]. The model was validated using thermoluminescent dosimetry (TLD) measurement. The absorbed dose for different exposure time in various culture planes has also been measured and verified. The exposure time for delivering doses of 100, 200, 400, 600, 800 and 1000 cGy are 36, 73.7, 154.6, 245.8, 345.1, 460.1 hours. Exponentially-growing CL187 cells in a tissue-culture flask (35 mm diameter) were irradiated using the above model. The cells were subsequently incubated for another 21 d at constant temperature and humidity. Irradiation was performed at the Zoology Institute of the Chinese Academy of Sciences.

**Clonogenic survival**

Clonogenic survival was defined as the ability of cells to maintain clonogenic capacity and to form colonies. Briefly, cells in the control and irradiation groups were exposed to different radiation dosages (0, 1, 2, 4, 6, 8, and 10 Gy). After incubation for 21 d, colonies were stained with crystal violet and manually counted. The plating efficiency (PE) and survival fraction (SF) were calculated as follows: PE = (colony number/inoculating cell number) × 100%. SF = PE (tested group)/PE (0-Gy group) × 100%. A dose-survival curve was obtained for each experiment and used for calculating several survival parameters. Parallel samples were set at each irradiation dosage. The cell-survival curve was plotted with Origin 7.5 software, using the equation: SF = 1 - (1 - e$^{-D/D_0}$)$^N$. The multi-target, single-hit model was applied to calculate cellular radiosensitivity (mean lethal dose, $D_0$), capacity for sublethal damage repair (quasithreshold dose, $D_q$), and extrapolation number (N). The $D_{10}$ values were used to calculate the relative biological effect (RBE).

**Cell cycle and apoptosis analysis**

Cells from the control and CLDR-treated groups were exposed to different radiation dosages (0, 2, 5, and 10 Gy). Cells were harvested 48 h after irradiation. For detection of apoptotic cells, cells were trypsinized, acridine orange stained, and determined under fluorescence microscope. At the same time, cells were counted and washed twice with cold PBS. Cells used for apoptosis tests were stained with propidium iodide (PI) and annexin V for 15 min in the dark. Cells used for cell-cycle testing were stained with propidium iodide after ethanol fixation and analyzed by fluorescence-activated cell sorting (FACS) using Coulter EPICS and ModFit software (Verity Software House, Topsham, MN). Each test was performed 3 times [19].

**EGFR and Raf quantifications by FCM**

Control and treated CL187 cells for EGFR and Raf quantifications by FCM were harvested 24 h after 4 Gy irradiation. Each test was performed 3 times. Cells used for tests were stained with Phospho-P38 EGFR mAb (Alexa Fluor) and Phospho-raf mAb (Alexa Fluor), and then analyzed by FACS using Coulter EPICS and ModFit software. Each test was performed 3 times [20-22].

**Statistical analysis**

Data were plotted as means ± standard deviation. Student’s t test was used for comparisons. Differences were considered significant at P < 0.05.

**Results**

**Survival curve of CL187 cells after different dose rate irradiation**

Data showed that cell-killing effects were related to dose rate. The survival curve of CL187 cells after different dose rate irradiation is shown in Figure 2. At the same dose, the survival fractions of $^{125}$I seeds were always lower than $^{60}$Co γ ray (Table 1). The cloning efficiency of CL187 was between 70% and 90%. Radiobiological parameters of
high dose rate irradiation treated CL187 cells were $D_0 = 1.85$, $D_q = 0.35$, and $N = 1.55$, while those of $^{125}$I seed low dose rate irradiation cells were $D_0 = 1.32$, $D_q = 0.14$, and $N = 1.28$. In the present study, $RBE = \frac{D_{10}^{\text{60Co}}}{D_{10}^{\text{125I}}} = 4.23/3.01 = 1.41$. The data presented herein suggested that the biological effect of $^{125}$I seed irradiation was stronger than that of $^{60}$Co $\gamma$ ray ($t = 2.578$, $P < 0.05$).

**Low dose rate irradiation-induced apoptosis and cell cycle arrest**

Cells were stained by acridine orange and observed under fluorescence microscopy; typical morphological features of apoptotic cells appeared after 5 Gy low dose rate irradiation (Fig. 3). FCM analysis showed that under low dose rate irradiation, apoptosis and G$_2$/M cell cycle arrest increased slightly at 2 Gy, the peak appeared at 5 Gy, and the ratio was also high at 10 Gy (Table 2) but lower than that at 5 Gy. Furthermore, G$_2$/M cell cycle arrest and apoptosis walked together along with the dose change ($r = 0.918$, $P < 0.01$, Fig. 4). Quantitative measurements of apoptotic cell death by FCM in CL187 cells sufficiently indicated that apoptosis is an important mechanism of low dose rate irradiation inhibition of CL187 cell proliferation.

**Expression changes of EGFR and Raf in CL187 cells after irradiation and/or EGFR monoclonal antibody treatment**

Under low dose rate irradiation, expression of EGFR ($74.27 \pm 5.63\%$) and Raf ($53.84 \pm 2.31\%$) was significantly higher than in the control group (Fig. 5 and Table 3). After signal transduction was blocked, expression of EGFR ($2.07 \pm 0.31\%$) and Raf ($13.74 \pm 1.82\%$) did not show detectable change after low dose rate irradiation (Fig. 5 and Table 3).

**Discussion**

Low-energy radioactive seed interstitial implantation has resulted in positive clinical treatment of many tumors previously radioresistant to high dose rate irradiation. This may be due to different radiobiological mechanisms between low and high dose rate irradiation. Nevertheless, compared with springing up of radioactive seeds interstitial implantation, fundamental research on this topic is notably absent, and the radiobiological mechanism of $^{125}$I seed low dose rate irradiation remains unclear.

As classic methods of appraising killing efficacy of irradiation, cell proliferation and clonic assays were used in the experiment. High dose rate irradiation killed tumor cells, but simultaneously induced radioresistance. However, the dose survival curve of $^{125}$I seed continuous low dose rate irradiation had no significant shoulder region, and SF was lower than $^{60}$Co $\gamma$ ray high dose rate irradiation. From the radiobiological parameter results, we also observed that $^{125}$I continuous low dose rate irradiation showed great advantages relative to high dose rate irradiation. Although RBE could be affected by many factors, such as cell line and dose rate, most studies have shown that the RBE of $^{125}$I was between 1.3 and 1.5. The present results are consistent with previous reports [24-27].

Our results indicated that apoptosis may play a central role regarding the observed killing effects when cells were exposed to $^{125}$I seed low dose rate irradiation [28,29]. Prior studies have suggested that radiosensitivity is cell cycle dependent, and cells in the G$_2$/M phase could be more radioresponsive [30]. These results suggest that CLDR may enhance radiosensitivity by inducing accumulation of cells in a more radiosensitive cell cycle phase (G$_2$/M) [31,32]. The apoptosis index of 10 Gy was lower than that of 5 Gy; two possibilities for this occurrence are: (a) Early-apoptotic cells disintegrated within the exposure time of 10 Gy, and could not be detected by FCM; and (b) Low dose rate irradiation only delayed the cell cycle, but could not completely block the cell cycle. Overshoot early irradiation, cells changed to be more radioresistant. Therefore, the apoptotic cells under 10 Gy were fewer than those under 5 Gy. Similarly, G$_2$/M arrest also declined under 10 Gy [33].

Our results indicated that the up-regulation of Raf expression correlated well with an increase in the level of EGFR expression after $^{125}$I seed irradiation [34-37]. It is suggested that the expression changes were all induced by CLDR. It is essential to prove that CLDR functioned via MAPK signal transduction. When the signal transduction...
Apoptosis of $^{125}$I low dose rate irradiation-treated CL187 cells. CL187 cells were stained with acridine orange, and determined under fluorescence microscope. There were no apoptotic cells in control groups (A), but typical morphological features of apoptosis appeared after 5 Gy CLDR irradiation (B). The apoptotic rates were detected by flow cytometry. In 2 Gy (D), 5 Gy (E), and 10 Gy (F) groups, the CL187 cells had higher apoptosis rates when compared with control groups (C). Concrete data see table 3. One of three experiments is shown. $P < 0.05$ vs. control group were found in every treated groups.
Figure 4
Effect of $^{125}$I low dose rate irradiation on the cell cycle in CL187 cells. Flow cytometry analysis revealed that the G$_2$/M phase increased by 2 Gy (B) $^{125}$I irradiation dose as compared with untreated control cells (A). After 5 Gy irradiation (C), a sharp increase in the fraction of cells in the G$_2$/M phase was observed. The result in 10 Gy irradiation groups (D) was lower than that in group C, but sustained at a relatively high level. Compared with untreated control cells, $P < 0.05$ were found in all of the treated groups.
was blocked by the EGFR monoclonal antibody, no obvious change in Raf expression occurred after $^{125}$I seed irradiation. It was proved that the necessary conditions were also sufficient [38,39]. These results formed the basis for combining CLDR with EGFR tyrosine kinase inhibitors in clinical practice [40,41,22].

In summary, our study provides a beneficial exploration of radiobiology of continuous low dose rate irradiation. Although many issues remain to be addressed, we believe that, with further development of fundamental research, application of $^{125}$I radioactive seed implantation in clinical practice will continue to be improved.

Table 2: Apoptosis index and cell cycle distribution after $^{125}$I low dose rate irradiation (% ± s).

|        | Apoptosis | G0/G1 | S       | G2/M     |
|--------|-----------|-------|---------|----------|
| Control| 1.67 ± 0.19 | 64.94 ± 5.87 | 8.62 ± 0.59 | 26.44 ± 2.53 |
| 2 Gy   | 13.74 ± 1.63a | 54.14 ± 3.16 | 11.25 ± 1.34 | 34.61 ± 2.79d |
| 5 Gy   | 46.27 ± 3.82b | 26.60 ± 2.82 | 13.56 ± 1.68 | 59.84 ± 4.96e |
| 10 Gy  | 32.58 ± 3.61c | 41.69 ± 4.58 | 15.72 ± 2.29 | 42.59 ± 3.21f |

Compared with control group (apoptosis), $t = 8.377$, $^{a}P < 0.05$; $t = 36.44$, $^{b}P < 0.01$; and $t = 27.35$, $^{c}P < 0.01$. Compared with control group (G2/M arrests), $t = 30.81$, $^{d}P < 0.05$; $t = 23.98$, $^{e}P < 0.05$; and $t = 26.3$, $^{f}P < 0.05$.

Figure 5
EGFR and Raf expression changes in CL187 cells after $^{125}$I irradiation and/or Anti-EGFR mAb. CLDR could influence the proliferation of cells via MAPK signal transduction. One representative of two experiments is shown.

Figure 5
EGFR and Raf expression changes in CL187 cells after $^{125}$I irradiation and/or Anti-EGFR mAb. CLDR could influence the proliferation of cells via MAPK signal transduction. One representative of two experiments is shown.
Table 3: Expression changes of EGFR and Raf in CL187 cells after irradiation and/or EGFR monoclonal antibody treatment (%).

|          | EGFR       | Raf       |
|----------|------------|-----------|
| Control  | 45.36 ± 3.91| 39.57 ± 3.48|
| 125I irradiation | 74.27 ± 5.63 | 53.84 ± 2.31 |
| Anti-EGFR mAb | 2.31 ± 0.19  | 14.68 ± 1.35 |
| 125I + Anti-EGFR mAb | 2.27 ± 0.13  | 13.74 ± 1.82 |

Compared with control group (EGFR), t = 54.84, **p < 0.01; t = 27.38, **p < 0.05**. Compared with anti-EGFR mAb group (EGFR), t = 1.21, **p > 0.05**. Compared with control group (Raf), t = 46.66, **p < 0.01**; and t = 26.60, **p < 0.01**. Compared with anti-EGFR mAb group (Raf), t = 0.98, **p > 0.05**.

Abbreviations
LDR: low-dose rate; HDR: high-dose rate; SLD: sublethal damage; SSB: single strand breaks; DSB: double strand breaks; ATM: ataxia-telangiectasia mutated; NHEJ: non-homologous end joining; HR: homologous recombination; HRS: hyper-radiosensitivity; RBE: relative biological effectiveness; PE: plating efficiency; SF: survival fraction; CLDR: continuous low-dose-rate; EGFR: epidermal growth factor receptor.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
HHQ carried out cell colony-forming assay, fluorescence-activated cell sorting, flow cytometric analysis, and drafted the manuscript. JJW participated in its design and revised the manuscript. AYL performed the statistical analysis. IDW carried out the irradiation experiment. YZ supervised experimental work and revised the manuscript. All authors read and approved the final manuscript.

Acknowledgements
The authors wish to thank Dr. Rui-jie Yang and Dong-Mei Tian for their critical reading of the manuscript, Ms. Jing Wang and Ms. Jian-Xia Peng for their expert technical assistance and Ms. Qing-Huan Li for her excellent laboratory management. This work was supported by a grant from the Ministry of Civil Affair, China ((2007)18).

References
1. Nath R, Anderson LL, Luxton G, Weaver KA, Williamson JF, Meigooni AS: Dosimetry of interstitial brachytherapy sources: recommendations of the AAPM Radiation Therapy Committee Task Group No. 43. Med Phys 1995, 22(2):209-234.
2. Aird EG, Folkard M, Hayes CR, Bowes PJ, Lawson JM, Joiner MC: A purpose built iodine-125 plaque for low dose rate low energy irradiation of cell lines in vitro. Br J Radiol 2001, 74(877):56-61.
3. Reniers B, Vynckier S, Verhaegen F: Theoretical analysis of microdosimetric spectra and cluster formation for Pd-103 and I-125 photon emitters. Int J Radiat Oncol Biol Phys 2004, 49(16):3781-3795.
4. Chen Z, Yue N, Wang X, Roberts KB, Peschel R, Nath R: Dosimetric effects of edema in permanent prostate seed implants: a rigorous solution. Int J Radiat Oncol Biol Phys 2000, 47(5):1405-1419.
5. Yu Y, Anderson LL, Li Z, Mellenberg DE, Nath R, Schell MC, Waterman FM, Wu A, Blasko JC: Permanent prostate seed implant brachytherapy: report of the American Association of Physicists in Medicine Task Group No. 64. Med Phys 1999, 26(10):2054-2076.
6. Wang J, Yuan H, Li J, Jiang W, Jiang Y, Tian S: Intestinal permanent implantation of 125I seeds as salvage therapy for recurrent rectal carcinoma. Int J Colorectal Dis 2009, 24(4):391-399.
7. Koutrouvelis PG: Computed tomography-guided salvage brachytherapy of recurrent large unresectable familial colorectal cancer in the pelvis: case report. Technol Cancer Res Treat 2002, 1(1):61-64.
8. Sakurai H, Mitsuhashi N, Harashima K, Muramatsu H, Ishikawa H, Kitamoto Y, Suzuki Y, Saiioh JI, Nonaka T, Akimoto T, Nakayama Y, Hambrok, Nakano T: CT-fluoroscopy guided interstitial brachytherapy with image-based treatment planning for unresectable locally recurrent rectal carcinoma. Brachytherapy 2004, 3(4):222-230.
9. Martínez-Monge R, Nag S, Martin EW: Three different intraoperative radiation modalities (electron beam, high-dose-rate brachytherapy, and iodine-125 brachytherapy) in the adjuvant treatment of patients with recurrent colorectal adenocarcinoma. Cancer 1999, 86(2):236-247.
10. Coatsour G, Truc G, Barillot I, Horiot JC, Maingon P: Treatment of T1–T2 rectal tumors by contact therapy and interstitial brachytherapy. Radiother Oncol 2004, 70(2):177-182.
11. Wang J, Yuan H, Ran W: Implantation of iodine-125 seed for head and neck carcinoma. Chin J Radiol Med Prot 2006, 26(1):56-59.
12. Conill C, Verger E, Marruecos J, Vargas M, Biete A: Low dose rate brachytherapy in lip carcinoma. Clin Transl Oncol 2007, 9(4):251-254.
13. Joyce F, Burchart F, Holm HH, Sroyer I: Ultrasound-guided percutaneous implantation of iodine-125 seeds in pancreatic carcinoma. Int J Radiat Oncol Biol Phys 1990, 19(4):1049-1052.
14. Montemaggi P, Dobelbower R, Crucitti F, Caracciolo F, Mongari AG, Smaniotto D, Luzi S, Cellini N: Intestinal brachytherapy for pancreatic cancer: report of seven cases treated with 125I and a review of the literature. Int J Radiat Oncol Biol Phys 1991, 21:451-457.
15. Harris J, Bruckner H: Adjuvant and Neoadjuvant Therapies of Pancreatic Cancer: A Review. Int J Gastrointest Cancer 2001, 29(1):8.
16. Nath R, Bongiorni P, Chen Z, Gragnano J, Rochwell S: Development of a rat solid tumor model for continuous low-dose-rate irradiation using studies of 125I and 103Pd sources. Brachytherapy 2004, 3(3):159-172.
17. Mirzae-Joniani H, Eriksson D, Sheikholvaezin A, Johansson A, Lofroth PO, Johansson L, Stibrand T: Apoptosis induced by low-dose-rate radiation. Cancer 94(4 Suppl):1210-1214.
18. Wang J, Wang J, Zhang H, Zhuang H, Zhao Y, Liao A: Development and validation of radioactive iodine-125 irradiator in vitro. Chin J Radiol Med Prot 2007, 27(3):267-271.
19. Sambrook J, David R: A Molecular Cloning Third Edition. America: CSHL Press; 2000:1235-1262.
20. Vávrová J, Rezácová M, Vokurková D, Psutka J: Ultrasound-guided percutaneous implantation of iodine-125 seeds in pancreatic carcinoma. Int J Radiat Oncol Biol Phys 1999, 45(1):1049-1052.
21. Harari PM, Allen GW, Bonner JA: Brachytherapy: therapy. Br J Radiol 1995, 68(805):236-247.
25. Nath R, Bongiorni P, Chen Z, Gragnano J, Rockwell S: Relative biological effectiveness of 103Pd and 125I photons for continuous low-dose-rate irradiation of Chinese hamster cells. Radiat Res 2005, 163(5):501-509.

26. Taschereau R, Roy R, Pouliot J: Relative biological effectiveness enhancement of a 125I brachytherapy seed with characteristic X rays from its constitutive materials. Med Phys 2002, 29(7):1397-1402.

27. Wu CS, Kliauga P, Zaider M, Amols HJ: Microdosimetric evaluation of relative biological effectiveness for 103Pd, 125I, 241Am, and 192Ir brachytherapy sources. Int J Radiat Oncol Biol Phys 1996, 36(3):689-697.

28. Short SC, Mitchell SA, Boulton P, Woodcock M, Joiner MC: The response of human glioma cell lines to low-dose radiation exposure. Int J Radiat Biol 1999, 75(11):1341-1348.

29. Mirzaie-Joniani H, Eriksson D, Johansson A, Lofroth PO, Johansson L, Ahlstrom KR, Stigbrand T: Apoptosis in HeLa Hep2 cells is induced by low-dose, low-dose-rate radiation. Radiat Res 2002, 158(3):634-40.

30. Mitchell CR, Joiner MC: Effect of subsequent acute-dose irradiation on cell survival in vitro following low dose-rate exposures. Int J Radiat Biol 2002, 78(11):981-990.

31. Keros SJ, Schwaninger MJ, Ntambi AJ, Keller TW, Nelson WG, Dillehay LE, Deweese TL: Evasion of early cellular response mechanisms following low level radiation-induced DNA damage. J Biol Chem 2004, 279(48):49624-49632.

32. Nakamura H, Yasui Y, Saito N, Tachibana A, Komatsu K, Ishizaki K: DNA repair defect in AT cells and their hypersensitivity to low-dose-rate radiation. Radiat Res 2006, 165(3):277-282.

33. Carlsson J, Hakansson E, Eriksson V, Grawe J, Wester K, Grussell E, Montelius A, Lundqvist H: Early effect of low-dose-rate radiation on cultured tumor cells. Cancer Biother Radiopharm 2003, 18(4):663-670.

34. Kruger LA, DeNardo GL, Gumerlock PH, Xiong CY, Winthrop MD, Shi XB, Mack PC, Leshchinsky T: Apoptosis-related gene and protein expression in human lymphoma xenografts after low dose-rate radiation using 67Cu-21T-BAT-Lym-1. Cancer Biother Radiopharm 2004, 16(3):213-225.

35. Chan KC, Knox WF, Gandhi A, Slamon DJ, Potten CS, Bundred NJ: Blockade of growth factor receptors in ductal carcinoma in situ inhibits epithelial proliferation. Br J Surg 2001, 88(3):412-418.

36. Cardillo F, Caputo R, Troiani T, Borrelli G, Kandimala ER, Agrawal S, Mendelsohn J, Blanco AR, Tortora G: Antisense oligonucleotides targeting the epidermal growth factor receptor inhibit proliferation, induce apoptosis, and cooperate with cytotoxic drugs in human cancer cell lines. Int J Cancer 2001, 93(2):172-178.

37. Baker CH, Kedar D, McCarty MF, et al.: Blockade of epidermal growth factor receptor signaling on tumor cells and tumor-associated endothelial cells for therapy of human carcinoma. Am J Pathol 2002, 161:929-938.

38. Lammering G, Valeri K, Lin PS, Mikkelsen RB, Contessa JN, Fanden J, Farnsworth J, Dent P, Schmidt-Ullrich RK: Radiosensitization of malignant glioma cells through overexpression of dominant-negative epidermal growth factor receptor. Clin Cancer Res 2001, 7(3):682-690.

39. Lammering G, Hewitt TH, Hawkins WT, Contessa JN, Reardon DB, Lin PS, Valeri K, Dent P, Kikkelson RB, Schmidt-Ullrich RK: Epidermal growth factor receptor as a genetic therapy target for carcinoma cell radiosensitization. J Natl Cancer Inst 2001, 93(12):921-929.

40. Zhu Z: Targeted cancer therapies based on antibodies directed against epidermal growth factor receptor: status and perspectives. Acta Pharmacol Sin 2007, 28(9):1476-1493.

41. Baselga J, Cortes J: Epidermal growth factor receptor pathway inhibitors. Cancer Chemother Biol Response Modif 2003, 22:205-23.